Transitioning from Cangrelor to Oral P2Y12 Inhibitors in Patients with ACS: Insights from the ARCANGELO Study
The use of cangrelor and the switch to any oral P2Y12 inhibitor in compliance with the EU SmPC is safe, with a low risk of ischemic events in routine clinical practice.
Authors
- Paolo Calabrò (ORCID: https://orcid.org/0000-0002-5018-830X)
- Alessio Mattesini (ORCID: https://orcid.org/0000-0001-8697-2692)
- Fabrizio Tomai (ORCID: https://orcid.org/0000-0002-2196-2941)
- Piera Capranzano (ORCID: https://orcid.org/0000-0001-8434-7367)
- Martino Pepe (ORCID: https://orcid.org/0000-0002-9235-1419)
- Ciro Mauro (ORCID: https://orcid.org/0000-0003-3611-2330)
- Sérgio Luis Berti (ORCID: https://orcid.org/0000-0002-5244-0556)
- Francesco Versaci (ORCID: https://orcid.org/0000-0003-2413-6693)
- Carlo Cernetti (ORCID: https://orcid.org/0000-0002-3158-477X)
- Plinio Cirillo (ORCID: https://orcid.org/0000-0001-7818-4952)
- Leonardo De Luca (ORCID: https://orcid.org/0000-0002-8552-1272)
- Giuseppe Musumeci (ORCID: https://orcid.org/0000-0001-6016-5702)
- Carlo Trani (ORCID: https://orcid.org/0000-0001-9777-013X)
- Elisa Nicolini (ORCID: https://orcid.org/0000-0003-2055-5516)
Institutions
- University of Rome Tor Vergata (IT)
- Agostino Gemelli University Polyclinic (IT)
- University of Catania (IT)
- Ospedale Antonio Cardarelli (IT)
- Aurelia Hospital (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- Tecnologie Avanzate (Italy) (IT)
- Ca' Foncello Hospital (IT)
- Ospedale Sant'Anna (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione Toscana Gabriele Monasterio (IT)
Publication Details
- Journal
- Current Vascular Pharmacology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.2174/0115701611309982250522065849
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00